Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerBilling CodesProprietary Laboratory AnalysesCPT cpt-0034u-tpmt-nudt15-genotyping-mayo-clinic
    Ask Trek AI about this page

    CPT 0034U: TPMT and NUDT15 Genotyping, Mayo Clinic

    CPT code 0034U is a Proprietary Laboratory Analyses (PLA) code for Thiopurine Methyltransferase (TPMT) and Nudix Hydrolase 15 (NUDT15) genotyping performed by Mayo Clinic to detect common genetic variants that affect thiopurine drug metabolism; service type: clinical molecular diagnostic genotyping; typical site of service: outpatient laboratory or specialized molecular diagnostics lab associated with Mayo Clinic.

    For related coverage guidance, see recent payer policy updates: Minimal Residual Disease (MRD) Testing for Cancer, Biomarker Testing Mandate, Prenatal (Fetal) Diagnostic Testing.

    Customize your policy alerts

    Sign up for cpt 0034U policy alerts

    Get alerted when payer policies referencing 0034U are released or updated.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Table of contents

    Progress1 / 7

    Explore openpayer tools

    • Billing CodesCPT, HCPCS, DRG & more
    • Reimbursement RatesCommercial vs. Medicare rate reports
    • Facility ComparisonBeds, revenue & payer mix
    • ProvidersHospitals & facilities
    • PayersPlans & market footprint
    • Taxonomy CodesNUCC specialty codes
    • ModifiersCPT modifiers & usage
    • Prior AuthorizationPA policies by payer & drug
    • Timely FilingFiling deadlines by payer
    • Coverage CriteriaMedical necessity by payer
    • Payer ContactsClaims, PA & appeals contacts
    View all tools

    Clinical & Coding Specifications

    Clinical Context

    A 10-year-old child with newly diagnosed acute lymphoblastic leukemia (ALL) is scheduled to begin maintenance therapy that includes thiopurine agents such as mercaptopurine. The oncology team orders pre-treatment pharmacogenetic testing to identify functional variants in thiopurine methyltransferase (TPMT) and nudix hydrolase 15 (NUDT15) that predict thiopurine metabolism and toxicity risk. A peripheral blood sample is collected in the outpatient infusion clinic or pediatric clinic and sent to Mayo Clinic’s laboratory for the proprietary genotyping assay reported with CPT code 0034U. The lab performs targeted genotyping for common TPMT and NUDT15 variants, generates a report indicating metabolizer status (e.g., normal, intermediate, poor), and the result is reviewed by the treating oncologist to inform thiopurine dosing and monitoring strategy. Typical sites of service include outpatient hospital laboratories, independent reference laboratories, pediatric oncology clinics, and inpatient hospital settings when pre-treatment testing is required prior to thiopurine administration. The service type is a proprietary laboratory analysis (PLA) molecular/genetic test specific to Mayo Clinic’s TPMT and NUDT15 genotyping assay.

    Related CPT Codes

    CPT CodeDescriptionRelationship to This Procedure
    81225CYP2C19 gene analysis, full genotype, common variant detection and interpretationPharmacogenetic testing that may be ordered alongside TPMT/NUDT15 when assessing broader drug metabolism profiles.
    81355HLA-B")" typing for HLA-B57:01 by molecular methodsAn example of a single-gene pharmacogenetic assay; conceptually related as targeted genotyping used to guide therapy.
    0042UProprietary molecular pathology test (example PLA)Other PLA codes for single-vendor proprietary assays; relates as examples of PLA billing practice.
    81162CYP2D6 gene analysis, common variantsAnother pharmacogenetic test often part of multi-gene panels that inform medication selection.
    0000UProprietary Laboratory Analyses examplePlaceholder representing other PLA tests; used operationally in lab workflows.

    Related Modifiers

    5 rows

    ModifierDescriptionWhen to Use
    90Modifier ‑90 (Reference/Outside Laboratory) indicates that a laboratory test was performed by an entity other than the treating or reporting provider. The American Medical Association defines…- Use CPT modifier -90 when a laboratory test is performed by an outside/reference laboratory (an entity other than the treating or reporting physician or qualified professional) and the claim needs…
    26Modifier 26 (Professional Component) identifies and bills only the professional portion of a split service — the physician’s interpretation, report, and medical judgment — when the technical…- Use CPT Modifier -26 when you are billing only the professional component (PC) of a split‑bill eligible service—i.e., you performed the physician interpretation, medical judgment and prepared a…
    59Modifier 59 indicates a distinct procedural service when two procedures that are not normally billed together are clinically and procedurally separate. The CPT definition (as reiterated by CMS)…- Use modifier -59 to report a distinct procedural service when documentation supports that the procedure reported is not normally billed together with another service on the same day because of a…
    91Modifier 91 — “Repeat Clinical Diagnostic Laboratory Test” — is appended when the exact same CPT laboratory test is performed more than once for the same patient on the same day because serial,…- Use modifier 91 when the exact same CPT laboratory test is performed more than once on the same patient on the same date because serial or repeated testing is medically necessary to monitor…
    82Modifier 82 is appended to a surgical CPT code to indicate that an attending physician acted as an assistant because a qualified resident surgeon was unavailable. In teaching hospitals it documents…- When to use: Append modifier 82 in teaching-hospital settings to indicate a physician served as an assistant surgeon because a qualified resident surgeon was unavailable (includes situations where…

    Related Provider Taxonomies

    8 rows

    Taxonomy Code
    207RC0000X
    207L00000X
    364S00000X
    163WP0218X
    225XP0200X
    1835P1300X
    235Z00000X
    204E00000X

    Related ICD-10-CM Codes

    29 rows

    ICD-10-CM CodeDescription
    C91.00Acute lymphoblastic leukemia not having achieved remission
    C91.02Acute lymphoblastic leukemia, in relapse
    C91.10Chronic lymphocytic leukemia of B-cell type not having achieved remission
    C92.00Acute myeloblastic leukemia, not having achieved remission
    C92.10Chronic myeloid leukemia, BCR/ABL-positive, not having achieved remission
    C95.00Acute leukemia of unspecified cell type not having achieved remission
    C95.10Chronic leukemia of unspecified cell type not having achieved remission
    D47.3Essential (hemorrhagic) thrombocythemia
    D86.9Sarcoidosis, unspecified
    D89.9Disorder involving the immune mechanism, unspecified

    Showing 1–10 of 29

    Related Payer Policy Updates

    Specialty: Genetic & Molecular Testing1 / 3

    10 rows

    PolicyPayerEffective Date
    Minimal Residual Disease (MRD) Testing for Cancerregence2027-01-01
    Biomarker Testing MandateBlue Cross Blue Shield - Rhode Island2027-01-01
    Prenatal (Fetal) Diagnostic TestingBlue Cross Blue Shield - Rhode Island2027-01-01
    Oral Cancer Screening and TestingOscar Health2027-01-01
    RTM Testing for Alpha-1 Antitrypsin DeficiencyOscar Health2027-01-01
    Cytochrome P450 Genotype-Guided Treatment Strategy Corporate Medical Policybcbsvermont2027-01-01
    Cytochrome P450 Genotypingblue cross blue shield - tennessee2026-12-31
    Polygenic Risk ScoreBlue Cross Blue Shield - Rhode Island2026-12-01
    Gene Expression Profiling for Cutaneous MelanomaBlue Cross Blue Shield - Rhode Island2026-12-01
    Genetic Variant Testing (Including Liquid Biopsy) for Targeted Treatment in Advanced Cancerblue_shield_of_california2026-11-01

    Related Codes

    CPT-0001U-PRECISETYPE-HEA-MULTIPLEX-RBC-ANTIGEN-GENOTYPING

    CPT 0001U: PreciseType HEA Erythrocyte Antigen Genotyping

    CPT-0002U-POLYPDX-URINE-METABOLOMIC-ASSAY-ADENOMATOUS-POLYP-RISK

    CPT 0002U: PolypDX™ Urine Metabolomic Risk Assay

    CPT-0003U-OVAR-A-NEXT-GENERATION-OVARIAN-CANCER-RISK-ASSAY

    CPT 0003U: Overa (MIA2G) Ovarian Cancer Risk Assay

    CPT-0005U-PROSTATE-EXOSOMEDX-INTELLISCORE-GENE-EXPRESSION-URINE-TEST

    CPT 0005U: ExosomeDx Prostate (IntelliScore) urine gene expression test

    CPT-0007U-TOXPROTECT-URINE-DRUG-SCREEN-WITH-DNA-AUTHENTICATION

    CPT 0007U: ToxProtect Urine Drug Screen With DNA Authentication

    CPT-0008U-H-PYLORI-ANTIBIOTIC-RESISTANCE-SEQUENCING-PANEL

    CPT 0008U: H. pylori Antibiotic Resistance Gene Panel

    CPT-0009U-DEPARRAY-HER2-FISH-TUMOR-CELL-ISOLATION

    CPT 0009U: DEPArray HER2 Tumor‑Cell Isolation with FISH Analysis

    CPT-0010U-BACTERIAL-TYPING-WHOLE-GENOME-SEQUENCING-MAYO-CLINIC

    CPT 0010U: Bacterial Typing by Whole Genome Sequencing, Mayo Clinic

    CPT-0011U-CORDANT-CORE-ALGORITHMIC-ORAL-FLUID-DRUG-TEST

    CPT 0011U: Oral Fluid Drug Test with Algorithmic Steady‑State Comparison

    CPT-0016U-BCR-ABL1-MAJOR-MINOR-FUSION-TRANSCRIPT-TESTING

    CPT 0016U: BCR–ABL1 Major and Minor Breakpoint Fusion Transcripts

    Showing 1–10 of 536

    • More pages

    Frequently Asked Questions

    References

    1. 1.CPT® Codes and Descriptions. AAPC. Retrieved Aug 11, 2026.Maintains the CPT code set's official descriptions and guidelines, licensed from the American Medical Association, used as the definitional source for CPT codes on this page.
    2. 2.HCPCS Quarterly Update. Centers for Medicare & Medicaid Services (CMS). Retrieved Aug 11, 2026.CMS's quarterly release of HCPCS Level II codes and short/long descriptors, the source for HCPCS code definitions and update history.
    3. 3.ICD-10-CM Full Code List. Centers for Medicare & Medicaid Services (CMS). Retrieved Aug 11, 2026.CMS's complete ICD-10-CM diagnosis code list, used to cross-reference diagnosis codes associated with this procedure or service.
    Published by

    Trek Health powers OpenPayer with a leading commercial payer intelligence platform, seamlessly converting fragmented payer data into actionable insights for provider organizations.

    Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.